Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers
Antibody drugs targeting a key growth factor receptor show strong activity against childhood rhabdomyosarcoma in laboratory and animal models, supporting advancement toward human testing.
NCI researchers report FGFR4-targeted ADCs using the 3A11 high-affinity antibody (same binder used in an ongoing CAR-T clinical trial, NCT06865664) achieve potent FGFR4-dependent cytotoxicity in rhabdomyosarcoma cell lines and robust tumor control in both fusion-negative RMS559 and fusion-positive RH4 xenograft models; exatecan-ADC outperforms MMAE-ADC with durable responses and retreatment efficacy in an FGFR4-expressing breast cancer model. This provides a clinical-development-ready rationale for FGFR4-ADC advancement in aggressive RMS, a pediatric tumor with dismal metastatic prognosis.
What the study was
- Study design
- preclinical_in_vitro_in_vivo
- Category
- novel_therapeutics_immunotherapy
- Maturity
- Exploratory
- Journal
- Cell Reports Medicine
Why it surfaced
Addresses a critical unmet need in relapsed/refractory RMS—a pediatric rare tumor with ~20% 5-year survival for metastatic disease—with an NCI-backed ADC paired to an ongoing phase I CAR-T trial. Score 7 (N=3, D=1, P=2, E=1) reflecting strong preclinical rationale and rare disease urgency.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.